Annual Secretarial Compliance for the year ended 31-March-2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Samrat Pharmachem Limited has filed its Annual Secretarial Compliance Report for FY 2025-26 (year ended March 31, 2026) as required under SEBI Regulation 24A. The report, issued by Practising Company Secretary Aqueel A. Mulla, confirms general compliance with SEBI regulations including LODR, ICDR, SAST, PIT, and other applicable regulations. The report identifies one current-year violation: delayed submission of the Annual Report for FY 2024-25, resulting in a BSE-imposed fine of Rs. 2,000 plus GST. A prior-year observation regarding delayed submission of voting results in XBRL mode was also noted, with the company having paid a fine of Rs. 10,000 plus tax. The company has no subsidiaries. Most compliance parameters including secretarial standards, document preservation, related party transactions, and performance evaluations were confirmed as compliant.
The filing is largely positive with compliance confirmed across most areas, though shareholders should note the recurring pattern of delayed regulatory submissions resulting in fines. While the amounts are minor, this indicates potential internal process gaps that could attract further regulatory scrutiny if not addressed.